静脉铁剂对终末期肾病透析患者贫血、微炎症及氧化应激的影响  

Effect of intravenous iron administration on anemia microinflammation and oxidative stress response in ESRD patients

作　　者：王港[1] 

机构地区：[1]湖北省黄石市中心医院肾内科,湖北黄石435002

出　　处：《海南医学院学报》2012年第1期43-44,47,共3页Journal of Hainan Medical University

基　　金：海南医学院科研基金资助学报项目(0020120011)~~

摘　　要：目的:探讨静脉铁剂对终末期肾病透析患者贫血、微炎症及氧化应激的影响。方法:将92例终末期肾病透析患者随机分为两组,均用重组人促红细胞生成素(rHuEPO)治疗,A组应用静脉铁剂,B组应用口服铁剂。结果:两组患者血清Hb、Hct水平较治疗前明显上升,rHuEPO用量较治疗前明显下降(P<0.05),且A组与B组比较差异显著(P<0.05)。A组患者血清CRP、IL-6、MDA水平较治疗前明显上升,GSH-Px较治疗前明显下降,且与B组比较差异显著(P<0.05)。结论:静脉铁剂可快速改善ESRD患者贫血状况,降低rhuEPO用量,但可诱发机体炎症及氧化应激反应。Objective： To explore the effect of intravenous iron administration on anemia microinflammation and oxidative stress response in ESRD patients.Methods：A total of 92 ESRD patients were randomly divided into intravenous iron administration group（groupA）,oral iron administration group（group B）.Both groups were given rHuEPO except iron administration Results：The Hb,HCT levels in two groups were significant higher than those before treatment,dosage of rHuEPO was reduced（P0.01）,which was more significant in group A（P0.05）.The CRP,IL-6,MDA levels of the group A were higher than that before treatment,while rHuEPO level was lower,and there were significantly differences between the two groups（P0.05）.Conclusions：Intravenous iron administration is effective for treating of anemia in ESRD patients,it can decrease the dosage of rhuEPO administration,but may aggravate oxidative stress and inflammation.

关 键 词：血液透析 贫血 微炎症 

分 类 号：R47[医药卫生—护理学]